Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]Cu-SAR-FAP
- Development stage
- Preclinical
- Lead developer
- Clarity Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[64Cu]Cu-SAR-FAP is a diagnostic radiopharmaceutical imaging agent developed by Clarity Pharmaceuticals for the detection and visualization of solid tumors. It consists of a fibroblast activation protein (FAP) inhibitor, derived from the small molecule UAMC1110, conjugated to a sarcophagine (SAR) chelator and radiolabeled with the positron-emitting isotope copper-64 (64Cu). FAP is a cell-surface protease that is highly overexpressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of most epithelial cancers, while remaining nearly undetectable in healthy adult tissues. The SAR chelator provides exceptional stability for the copper radioisotope, preventing transchelation and ensuring high-contrast PET imaging with prolonged tumor retention. This agent is part of Clarity's Targeted Copper Theranostic (TCT) platform, designed to be paired with copper-67 for therapeutic applications.
- Other names
- 64Cu-SAR-FAP
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on [64Cu]Cu-SAR-FAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [64Cu]Cu-SAR-FAP.